FVIII administration in surgery

Haemophilia

Volumn 17, Issue 5, 2011, Pages 828-829

  Ewenstein, B ^a   Wong, W Y ^a   Casey, K ^a   Alai, M ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

BLEEDING; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; HEMOPHILIA A; HEMOSTASIS; HUMAN; LETTER; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; FACTOR VIII; HEMOPHILIA A; HUMANS; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS;

EID: 80052038301     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02594.x     Document Type: Letter

References (5)

1. Collins PW, Björkman S, Fischer K et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-75.
2. Négrier C, Shapiro A, Berntorp E et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. Thromb Haemost 2008; 100: 217-23.
3. Scharrer I. Experience with KOGENATE Bayer in surgical procedures. Haemophilia 2002; 8(Suppl. 2): 15-8.
4. Stieltjes N, Altisent C, Auerswald G et al. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience. Haemophilia 2004; 10: 452-8.
5. Fernandez M, Yu T, Bjornson E, Luu H, Spotts G. Stability of ADVATE, antihemophilic factor (recombinant) plasma/albumin-free method, during simulated continuous infusion. Blood Coagul Fibrinolysis 2006; 17: 165-71.